Secondary outcome (Figure 4)
Secondary outcomes included mortality, hospitalization for any cause and
Sustained decrease of >/= 57% in eGFR from baseline. 3 of
the 5 studies reported all the outcomes [5,10,14]. The pooled analysis revealed that treatment with Finerenone was
associated with a reduced risk of the aforementioned outcomes (RR = 0.90
[0.83, 0.97] p=0.006; I2= 0%), (RR = 0.97 [0.94, 0.99] p=0.02;
I2= 0%) and (RR = 0.71 [0.64, 0.79] p <0.00001; I2= 0%),
respectively.